Guggenheim Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Guggenheim Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,718	Closed	-$765K	–	2905
2016 Q1	$765K	Sell	5,718 -1,967	-26%	-$217K	﹤0.01%	2199
2015 Q4	$1.53M	Sell	7,685 -1,156	-13%	-$250K	﹤0.01%	1810
2015 Q3	$1.4M	Sell	8,841 -406	-4%	-$109K	﹤0.01%	1872
2015 Q2	$3.77M	Buy	9,247 +530	+6%	+$229K	0.01%	1305
2015 Q1	$4M	Sell	8,717 -3,900	-31%	-$1.68M	0.01%	1285
2014 Q4	$7.08M	Buy	12,617 +6,941	+122%	+$3.94M	0.02%	967
2014 Q3	$2.98M	Sell	5,676 -329	-5%	-$186K	0.01%	1487
2014 Q2	$4.19M	Buy	6,005 +1,116	+23%	+$519K	0.01%	1293
2014 Q1	$2.27M	Buy	+4,889	New	+$2.48M	0.01%	1692

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Guggenheim Capital's KPTI Position: Q2 2016 in Review

Guggenheim Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2016, closing a stake of 5,718 shares — an estimated $765K sold.

Guggenheim Capital first reported a position in KPTI in Q1 2014 and held it in 9 quarters. The position peaked at $7.08M in Q4 2014. 75 funds tracked by Wall St. Rank hold KPTI as of Q2 2016.

Guggenheim Capital reported no remaining Karyopharm Therapeutics position as of Q2 2016 after selling out during the quarter.
Guggenheim Capital sold 5,718 Karyopharm Therapeutics shares in Q2 2016, an estimated $765K.
Guggenheim Capital first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 9 quarters.
Guggenheim Capital's Karyopharm Therapeutics position peaked at $7.08M in Q4 2014.
75 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2016.

Based on Guggenheim Capital's 13F filing for Q2 2016, filed 15 Aug 2016.